Liposomes of dimeric artesunate phospholipid: A combination of dimerization and self-assembly to combat malaria

Ismail, Muhammad; Ling, Longbing; Du, Yawei; Chen, Yao; Li, Xinsong

doi:10.1016/j.biomaterials.2018.02.026

Cited by 66 publications

(39 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 According to the WHO, malaria is one of the world's most lethal diseases which caused 214 million new infections and nearly 438,000 malaria-associated deaths in 2015 worldwide. 1,3,4 More than 216 million people are still infected by the malarial parasite each year. 5 Although the disease is widespread, it is most severe in tropical and subtropical regions.…”

Section: Introductionmentioning

confidence: 99%

<p>Nano-biotechnology: a new approach to treat and prevent malaria</p>

Rahman¹,

Khan²,

Fahad³

et al. 2019

IJN

View full text Add to dashboard Cite

Malaria, the exterminator of ~1.5 to 2.7 million human lives yearly, is a notorious disease known throughout the world. The eradication of this disease is difficult and a challenge to scientists. Vector elimination and effective chemotherapy for the patients are key tactics to be used in the fight against malaria. However, drug resistance and environmental and social concerns are the main hurdles in this fight against malaria. Overcoming these limitations is the major challenge for the 21st-century malarial researchers. Adapting the principles of nano-biotechnology to both vector control and patient therapy is the only solution to the problem. Several compounds such as lipids, proteins, nucleic acid and metallic nanoparticles (NPs) have been successfully used for the control of this lethal malaria disease. Other useful natural reagents such as microbes and their products, carbohydrates, vitamins, plant extracts and biodegradable polymers, are also used to control this disease. Among these particles, the plant-based particles such as leaf, root, stem, latex, and seed give the best antagonistic response against malaria. In the present review, we describe certain efforts related to the control, prevention and treatment of malaria. We hope that this review will open new doors for malarial research.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Nano-biotechnology: a new approach to treat and prevent malaria</p>

Rahman¹,

Khan²,

Fahad³

et al. 2019

IJN

View full text Add to dashboard Cite

show abstract

“…Apart from these fiber-or micelle-like morphologies, varieties of liposome-like small molecule nanodrugs have been developed. [36][37][38][39][40][41][42][43] Many of these nanodrugs have similar conjugate structure containing phospholipids.…”

Section: Small Molecule Nanodrugs Overcoming In Vitro "Barriers"mentioning

confidence: 99%

“…(B) In vitro cytotoxicity of CPT, OEG-DiCPT, DOX⋅HCl, and OEG-DiCPT/DOX⋅HCl to MCF-7 breast cancer cells determined by MTT assay. 73 Copyright 2010, American Chemical Society stearic acid, 78 lauric acid, 79 phospholipid, [39][40][41][42][43] and so forth have been reported for self-assembled drug delivery. For example, Shen et al 73 reported the concept of directly using ethylene oxide oligomer to construct nanocarriers in order to minimize use of inert materials, substantially increase the drug loading content, and suppress premature burst release.…”

Section: Drug Derivativesmentioning

confidence: 99%

“…116 Zwitterionic phospholipid has been widely used to prepare the amphiphilic drug derivatives. [36][37][38][39][40][41][42][43]117,118 For example, artesunate was conjugated to phospholipid form dimeric artesunate phospholipid-based liposomes. Compared to the free drug artesunate, the blood clearance time of zwitterionic liposomes was significantly prolonged.…”

Section: Small Molecule Nanodrugs Overcoming Blood Barriermentioning

confidence: 99%

See 1 more Smart Citation

Engineering small molecule nanodrugs to overcome barriers for cancer therapy

Mou

Yan

et al. 2020

VIEW

View full text Add to dashboard Cite

Small molecule nanodrugs consisting of pure drugs, drug‐drug dimers, drug‐drug conjugates, or drug derivatives could realize drug delivery by themselves without the aid of carriers, which have received abundant attention in recent decades. Avoiding the use of additional carriers, the yielded small molecule nanodrugs hold the following advantages: (a) high drug loading capacities (some of them could even reach up to 100%); (b) precise and tunable drug loading ration; and (c) no carrier‐induced long‐term toxicity. The past decade has witnessed rapid growth and advancements in this field. In this review, we will briefly introduce both in vitro “barriers” and in vivo barriers for drug delivery, and then summarize the most recent development of small molecule nanodrugs from the point of view how to engineer small molecule nanodrugs to overcome these barriers.

show abstract

“…They are biocompatible and allow for the controlled release of both hydrophilic and hydrophobic drugs. Compared to other nanoparticle systems, they demonstrated better capability to enhance the selectivity index of drugs by prolonging systemic circulation time and minimizing toxicity and immunogenicity [12]. In vivo assays performed with liposomes of artemisinin demonstrated a much longer blood circulation time than free artemisinin [13], hence demonstrating a good strategy for the development of therapeutics to treat parasitic diseases.…”

Section: Introductionmentioning

confidence: 99%

Heparin-Coated Liposomes Improve Antiplasmodial Activity and Reduce the Toxicity of Poupartone B

Ledoux

Mamede

Palazzo

et al. 2020

Planta Medica International Open

View full text Add to dashboard Cite

Poupartone B is an alkyl cyclohexenone derivative isolated from Poupartia borbonica. This compound demonstrated promising antimalarial activity (IC50 < 1 µg/mL), however, it was not devoid of toxicity. Thus, to reduce the adverse side effects of this natural bioactive molecule, a delivery strategy involving a nanostructure was formulated. Additionally, poupartone B-loaded liposomes were coated with heparin, a glycosaminoglycan that is known to target proteins on the surface of Plasmodium falciparum-infected red blood cells. The quantification of the compound in the formulation was performed by HPLC-DAD, while heparin was quantitated by 1H NMR spectroscopy. The liposomes’ antiplasmodial activity was tested on artemisinin-resistant P. falciparum isolate, and toxicity was evaluated on human HeLa cells and zebrafish embryos. Throughout this research, the formulation demonstrated higher antiplasmodial activities against both P. falciparum strains and a significant decrease of in vitro toxicity. The formulation improved the selectivity index 2 times in vitro and proved to be 3 times less toxic than the compound alone in the zebrafish embryo acute toxicity test. Hence, the use of this strategy to deliver natural products in Plasmodium-infected cells, particularly those with a narrow therapeutic margin, is proposed.

show abstract

Liposomes of dimeric artesunate phospholipid: A combination of dimerization and self-assembly to combat malaria

Cited by 66 publications

References 53 publications

<p>Nano-biotechnology: a new approach to treat and prevent malaria</p>

<p>Nano-biotechnology: a new approach to treat and prevent malaria</p>

Engineering small molecule nanodrugs to overcome barriers for cancer therapy

Heparin-Coated Liposomes Improve Antiplasmodial Activity and Reduce the Toxicity of Poupartone B

Contact Info

Product

Resources

About